These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 36165835)

  • 1. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products.
    Ibrahim M; Ramadan E; Elsadek NE; Emam SE; Shimizu T; Ando H; Ishima Y; Elgarhy OH; Sarhan HA; Hussein AK; Ishida T
    J Control Release; 2022 Nov; 351():215-230. PubMed ID: 36165835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective.
    Tenchov R; Sasso JM; Zhou QA
    Bioconjug Chem; 2023 Jun; 34(6):941-960. PubMed ID: 37162501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylated liposomes: immunological responses.
    Mohamed M; Abu Lila AS; Shimizu T; Alaaeldin E; Hussein A; Sarhan HA; Szebeni J; Ishida T
    Sci Technol Adv Mater; 2019; 20(1):710-724. PubMed ID: 31275462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
    Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
    J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
    Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
    Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
    Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
    Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.
    Takata H; Shimizu T; Yamade R; Elsadek NE; Emam SE; Ando H; Ishima Y; Ishida T
    J Control Release; 2023 Aug; 360():285-292. PubMed ID: 37355210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement.
    Estapé Senti M; de Jongh CA; Dijkxhoorn K; Verhoef JJF; Szebeni J; Storm G; Hack CE; Schiffelers RM; Fens MH; Boross P
    J Control Release; 2022 Jan; 341():475-486. PubMed ID: 34890719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylated liposomes for diagnosis of polyethylene glycol allergy.
    Perkins GB; Tunbridge MJ; Hurtado PR; Zuiani J; Mhatre S; Yip KH; Le TA; Yuson C; Kette F; Hissaria P
    J Allergy Clin Immunol; 2024 Aug; 154(2):503-507.e1. PubMed ID: 38718949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
    Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
    Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
    Carreño JM; Singh G; Tcheou J; Srivastava K; Gleason C; Muramatsu H; Desai P; Aberg JA; Miller RL; Study Group P; Pardi N; Simon V; Krammer F
    Vaccine; 2022 Oct; 40(42):6114-6124. PubMed ID: 36115801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Pre-Existing Antibodies to Polyethylene Glycol and PEGylated Liposomes in Human Serum.
    Neun BW; Dobrovolskaia MA
    Methods Mol Biol; 2024; 2789():185-192. PubMed ID: 38507004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies.
    Chen BM; Cheng TL; Roffler SR
    ACS Nano; 2021 Sep; 15(9):14022-14048. PubMed ID: 34469112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals.
    Kozma GT; Shimizu T; Ishida T; Szebeni J
    Adv Drug Deliv Rev; 2020; 154-155():163-175. PubMed ID: 32745496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine.
    Münter R; Sørensen E; Hasselbalch RB; Christensen E; Nielsen SD; Garred P; Ostrowski SR; Bundgaard H; Iversen KK; Andresen TL; Larsen JB
    Mol Pharm; 2023 Jul; 20(7):3356-3366. PubMed ID: 36952227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.
    Shi D; Beasock D; Fessler A; Szebeni J; Ljubimova JY; Afonin KA; Dobrovolskaia MA
    Adv Drug Deliv Rev; 2022 Jan; 180():114079. PubMed ID: 34902516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
    Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
    J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Induction of Anti-PEG Immune Responses by PEGylation of Proteins].
    Shimizu T; Ishima Y; Ishida T
    Yakugaku Zasshi; 2020; 140(2):163-169. PubMed ID: 32009039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines.
    Chen WA; Chang DY; Chen BM; Lin YC; Barenholz Y; Roffler SR
    ACS Nano; 2023 Mar; 17(6):5757-5772. PubMed ID: 36926834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
    Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.